Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Extended-release bupropion hydrochloride Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

NCT00865371
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

NCT04388319
View directory record Official record
Conditions
Smoking Cessation
Interventions
Zonisamide, Bupropion, Halo G6 e-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 2, 2026, 1:38 AM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Lethargic Depression Study

NCT00064467
View directory record Official record
Conditions
Epilepsy, Major Depressive Disorder (MDD)
Interventions
Extended-release bupropion (HCl)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111
View directory record Official record
Conditions
Healthy
Interventions
Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 2, 2026, 1:38 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

NCT00865410
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 2, 2026, 1:38 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

NCT00048360
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT01077024
View directory record Official record
Conditions
Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions
Smoking-cessation treatment
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 2, 2026, 1:38 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 2, 2026, 1:38 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 2, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

NCT06374290
View directory record Official record
Conditions
Smoking Cessation
Interventions
Naltrexone (Vivitrol), Bupropion
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 2, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia

NCT03132571
View directory record Official record
Conditions
Schizophrenia, Diabetes Mellitus, Type 2, Obesity
Interventions
Naltrexone, Bupropion, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 2, 2026, 1:38 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

NCT03078075
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Seasonal Affective Depression (SAD) Study

NCT00069459
View directory record Official record
Conditions
Depressive Disorder
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 2, 2026, 1:38 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

NCT06098079
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone-Bupropion (NB) Combination, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
140
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
View directory record Official record
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 2, 2026, 1:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

NCT01982643
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
naltrexone plus bupropion
Drug
Lead sponsor
Walter Ling
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 2, 2026, 1:38 AM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 1:38 AM EDT